Regen BioPharma, Inc. Presents Preclinical Proof-of-Concept of DiffronC Effectiveness at the International Society for Stem Cell Research (ISSCR) Annual Meeting

Jul 14, 2015, 08:30 ET from Regen BioPharma, Inc.

SAN DIEGO, Jul. 14, 2015 /PRNewswire/ --Regen BioPharma Inc  (OTCBB: RGBP) (OTC PINK: RGBP) announced today that Dr. Christine Ichim, the Company's Director of Molecular Therapeutics presented preclinical data regarding its DiffronC technology( a constituent of its Differentiation Therapy Platform) at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden on June 24th, 2015.

A feature of acute leukemia is that normal blood cells transform into cells that remain immature because they are blocked in their ability to differentiate. In other words, when normal bone marrow cells turn leukemic they lose their natural ability to mature into functional blood cells. The company's Differentiation Therapy Platform aims to coax stem cells with blocked differentiation to mature into normal blood cells which function and then will eventually die. DiffronC is an oligonucleotide based product that is designed to induce differentiation of cancer stem cells by silencing of nuclear receptor targets important in keeping stem cells in an undifferentiated state.

The presentation provided the mechanism of action for DiffronC, showing that the gene targeted by DiffronC functions to block the differentiation of blood stem cells preventing their maturation in to healthy blood cells.

This presentation further provided pre-clinical proof-of-concept that DiffronC caused blood forming stem and progenitor cells to differentiate in to mature blood cells.  These results provide a foundation for use of the DiffronC gene silencing technology as differentiation therapy for blood disorders that have blocked differentiation, such as leukemia and myelodysplastic syndromes.

"We are very excited that our presentation was so well received at the prestigious ISSCR meeting. The ISSCR is the premier event for translational stem cell research in the world, attended by more than 3500 international attendees. We are very proud that our scientists were amongst the prestigious scientists in attendance, " said David Koos, Chairman and CEO of Regen BioPharma Inc.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION
Regen BioPharma Inc. 
David R. Koos, PhD 
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
www.regenbiopharma.com

SOURCE Regen BioPharma, Inc.



RELATED LINKS

http://www.regenbiopharma.com